Skip to main content
SpringerLink
Log in

Circulating calprotectin as a biomarker of laryngeal carcinoma

  • Laryngology
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Calprotectin is an S100 protein and marker of inflammation found in neutrophils and monocytes; S100 proteins are a family of calcium-modulated proteins. The aim of this study was to determine if the serum concentration of calprotectin is higher in patients with laryngeal carcinoma than in patients with benign laryngeal pathologies and controls. The study included 107 participants. The serum calprotectin concentration was analyzed using the calprotectin ELISA (enzyme-linked immunosorbent assay) kit (Calpo AS, Norway). EDTA-serum for analysis was collected prior to surgery from patients with laryngeal carcinoma (n = 41), those with a benign laryngeal pathology (Reinke’s edema, vocal nodules, etc.) (n = 32), and healthy controls (n = 34). The median serum calprotectin concentration was significantly higher in the laryngeal carcinoma group (2179.6 μg L−1) than in the benign laryngeal pathology group (727.84 μg L−1) and control group (733.73 μg L−1) (P < 0.05). The median serum calprotectin concentration in patients with advanced-stage laryngeal cancer (5854.,4 μg L−1) was significantly higher than in those with early-stage laryngeal cancer (971.84 μg L−1) (P < 0.05); however, there was not a significant difference in the median calprotectin concentration between the control and benign laryngeal pathology groups (P > 0.05). Furthermore, the median serum calprotectin concentration in the patients with early-stage laryngeal cancer (n = 21) (971.84 μg L−1) was significantly higher than that in the benign laryngeal pathology and control groups (n = 64) (730.6 μg L−1) (P < 0.05). The serum calprotectin concentration was strongly correlated with poor survival and advanced-stage laryngeal carcinoma. Malignant laryngeal cancer patients (n = 4) that died during follow-up had a higher median serum calprotectin concentration (9468.4 μg L−1) than those that remained alive (n = 37) (857.78 μg L−1) (P < 0.05). The serum calprotectin concentration is higher in patients with laryngeal carcinoma than in those with benign laryngeal pathologies and healthy controls. The present findings show that the serum calprotectin concentration might be used as a marker to discriminate between laryngeal carcinoma and benign laryngeal pathologies. Additional research is needed to further assess the value of this parameter as a useful tumor marker for the diagnosis, treatment, and follow-up of laryngeal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hashibe M, Boffetta P, Zaridze D, et al. (2007) Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol 165(7):814–820

    Article  PubMed  Google Scholar 

  2. Lin HW, Bhattacharyya N (2008) Staging and survival analysis for nonsquamous cell carcinomas of the larynx. Laryngoscope 118(6):1003–1013

    Article  PubMed  Google Scholar 

  3. Coussens LM, Werb Z (2002) Review Inflammation and cancer. Nature 420(6917):860–867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gebhardt C, Nement J, Angel P, Hess J (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Phamacol 72:1622–1631

    Article  CAS  Google Scholar 

  5. Kristinsson J, Roseth A, Fagerhol MK, Aadland E, Schjonsby H, Bormer OP, et al. (1998) Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321

    Article  CAS  PubMed  Google Scholar 

  6. Strız I, Trebıchavsky I (2004) Calprotectin—a pleoiotropic molecule in acute and chronic ınflammation Physiol Res 53:245–253

    PubMed  Google Scholar 

  7. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, et al. (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6826

    CAS  PubMed  Google Scholar 

  8. Dale I, Brandtzaeg P (1989) Expression of the epithelial L1 antigen as an immunhistochemical marker of squamous cell carcinoma of the lung. Histopathology 14:493–502

    Article  CAS  PubMed  Google Scholar 

  9. Brahian H, Trovik J, Wik E, Stefansson I, Akslen LA, Salvesen HB, Staff AC (2009) Plasma calprotectin concentrations in woman with endometrial carcinoma. Gynecol Oncol 114:491–495

    Article  Google Scholar 

  10. Yui S, Nakatani Y, Mikami M Calprotektin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity (2003) Biol Pharm Bull 26:753–760

    Article  CAS  PubMed  Google Scholar 

  11. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinase. J Biol Chem 274:21491–21494

    Article  CAS  PubMed  Google Scholar 

  12. Qiu G, Li Y, Liu Z, Wang M, Ge J, Bai X (2014) Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol 31:316

    Article  PubMed  Google Scholar 

  13. Aria K, Yamada T, Nozawa R (2000) İmmunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol 17:183–188

    Article  Google Scholar 

  14. Harmani A, Hess J, Servi BD, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D(2005) Calcium-Binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11:5146–5152

    Article  Google Scholar 

  15. Ott HW, Lindner H, Sarg B et al. (2003) Calgranulins in cystic fluids and serum from patients with ovarian carcinomas. Cancer Res 63:7507–7514

    CAS  PubMed  Google Scholar 

  16. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R (2004) S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 40:1179–1187

    Article  CAS  PubMed  Google Scholar 

  17. Kristinsson J, Roseth A, Fagerhol MK, et al. (1998) Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 41:316–321

    Article  CAS  PubMed  Google Scholar 

  18. Odegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, et al. (2008) Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol 198:418e1–418e7

    Article  Google Scholar 

Download references

Acknowledgements

We offer our thanks to Calpro AS, Norway for providing the calprotectin assays.

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, Dumlupinar University School of Medicine, Istiklal Parish Okmeydanı st. No: 5 Merkez, Kütahya, Turkey

    Muhammet Fatih Topuz

  2. Department of Otorhinolaryngology, Marmara University School of Medicine, Fevzi Çakmak Parish Muhsin Yazıcıoğlu st. No: 10 Kaynarca, Pendik, Istanbul, Turkey

    Adem Binnetoglu, Ali Cemal Yumusakhuylu, Murat Sarı & Tekin Baglam

  3. Central Laboratory of Public Health, Yakuplu Parish Acelya st. No: 1 Beylikdüzü, Istanbul, Turkey

    Fetullah Gerin

Authors
  1. Muhammet Fatih Topuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adem Binnetoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Cemal Yumusakhuylu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Murat Sarı
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tekin Baglam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fetullah Gerin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammet Fatih Topuz.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Funding

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Topuz, M.F., Binnetoglu, A., Yumusakhuylu, A.C. et al. Circulating calprotectin as a biomarker of laryngeal carcinoma. Eur Arch Otorhinolaryngol 274, 2499–2504 (2017). https://doi.org/10.1007/s00405-017-4480-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-017-4480-4

Keywords

Search

Navigation